NO20042298L - Pharmaceutical preparations and their uses - Google Patents
Pharmaceutical preparations and their usesInfo
- Publication number
- NO20042298L NO20042298L NO20042298A NO20042298A NO20042298L NO 20042298 L NO20042298 L NO 20042298L NO 20042298 A NO20042298 A NO 20042298A NO 20042298 A NO20042298 A NO 20042298A NO 20042298 L NO20042298 L NO 20042298L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparations
- compositions
- dihydropiridin
- immunoregulatory
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
The present invention relates to compositions comprising 1,2-dihydropiridin-2-one compounds and an immunoregulatory or anti-inflammatory agent. The compositions are useful for the prevention or the treatment of neurodegenerative diseases, for example demyelinating disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129260.6A GB0129260D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical compositions and their uses |
PCT/GB2002/005542 WO2003047577A2 (en) | 2001-12-06 | 2002-12-06 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20042298L true NO20042298L (en) | 2004-09-06 |
NO333627B1 NO333627B1 (en) | 2013-07-29 |
Family
ID=9927156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042298A NO333627B1 (en) | 2001-12-06 | 2004-06-03 | A pharmaceutical composition comprising a 1,2-dihydropyridin-2-one compound and an interferon, as well as their use in the treatment of demyelination disorders |
Country Status (24)
Country | Link |
---|---|
US (1) | US7759367B2 (en) |
EP (1) | EP1465626B1 (en) |
JP (1) | JP4610898B2 (en) |
KR (1) | KR100945822B1 (en) |
CN (1) | CN1738618B (en) |
AT (1) | ATE406893T1 (en) |
AU (1) | AU2002347365B2 (en) |
BR (2) | BR0214705A (en) |
CA (1) | CA2469076C (en) |
CY (1) | CY1108578T1 (en) |
DE (1) | DE60228761D1 (en) |
DK (1) | DK1465626T3 (en) |
ES (1) | ES2311635T3 (en) |
GB (1) | GB0129260D0 (en) |
HU (1) | HU228328B1 (en) |
IL (2) | IL162214A0 (en) |
MX (1) | MXPA04005376A (en) |
NO (1) | NO333627B1 (en) |
NZ (1) | NZ533798A (en) |
PT (1) | PT1465626E (en) |
RU (1) | RU2358733C2 (en) |
SI (1) | SI1465626T1 (en) |
WO (1) | WO2003047577A2 (en) |
ZA (1) | ZA200404330B (en) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6949571B2 (en) | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
SE0302487D0 (en) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
CA2545813C (en) * | 2003-11-14 | 2011-01-04 | Shanghai Genomics, Inc. | The derivatives of pyridone and use thereof |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
CA2553923A1 (en) | 2004-01-22 | 2005-08-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005099688A2 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
MY148809A (en) * | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
JP2007099781A (en) * | 2004-07-06 | 2007-04-19 | Eisai R & D Management Co Ltd | Method for producing crystal of 1,2-dihydropyridine compound |
BRPI0517947A (en) | 2004-11-02 | 2008-10-21 | Univ Northwestern | pyridazine compound, compositions and methods |
WO2006050359A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
ME01224B (en) * | 2005-04-04 | 2013-06-20 | Eisai R&D Man Co Ltd | Dihydropyridine compounds for neurodegenerative diseases and dementia |
AU2006234627C1 (en) * | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
US7728013B2 (en) | 2005-05-10 | 2010-06-01 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
DE602006020293D1 (en) * | 2005-08-29 | 2011-04-07 | Vertex Pharma | 3,5-DISUBSTITUTED PYRID-2-ONE, WHICH ARE USES AS INHIBITORS OF THE TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES |
JP2009507792A (en) | 2005-08-29 | 2009-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3,5-Disubstituted pyrid-2-ones useful as inhibitors of the TEC family of non-receptor tyrosine kinases |
AU2006284900A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
KR101420445B1 (en) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
JP4865337B2 (en) * | 2006-01-24 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | Process for producing 2,3'-bipyridyl-6'-one |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
WO2007126060A1 (en) * | 2006-04-28 | 2007-11-08 | Eisai R & D Management Co., Ltd | Salt of 1,2-dihydropyridine compound |
CN101754762A (en) | 2006-04-28 | 2010-06-23 | 西北大学 | The preparation that comprises pyridazine compound that is used for the treatment of neuroinflammatory disorder |
WO2007127475A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
WO2007127474A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
AU2007272830B2 (en) | 2006-07-14 | 2011-07-28 | Amgen Inc. | Alkyne-substituted pyridone compounds and methods of use |
US8920808B2 (en) | 2006-10-31 | 2014-12-30 | East Carolina University | Cytokine-based fusion proteins for treatment of multiple sclerosis |
WO2008093392A1 (en) * | 2007-01-29 | 2008-08-07 | Fujifilm Finechemicals Co., Ltd. | Process for production of 2,3’-bipyridyl-6’-one |
EP2131828A2 (en) * | 2007-03-05 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
JP2010524844A (en) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Cinnamide compounds for dementia |
TWI445532B (en) | 2007-09-14 | 2014-07-21 | Janssen Pharmaceuticals Inc | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
JP2011502982A (en) * | 2007-11-06 | 2011-01-27 | アストラゼネカ・アクチエボラーグ | Certain 2-pyrazinone derivatives and their use as inhibitors of neutrophil elastase |
CN101952274A (en) * | 2007-11-20 | 2011-01-19 | 默沙东公司 | Non-nucleoside reverse transcriptase inhibitor |
CN101883757B (en) * | 2007-12-21 | 2013-06-12 | 株式会社可乐丽 | Method for producing 6-halogeno-3-arylpyridine derivative |
WO2009082038A2 (en) * | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
EP2350096B1 (en) | 2008-10-02 | 2019-12-11 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
MX2011004570A (en) * | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | P2x3, receptor antagonists for treatment of pain. |
WO2010054307A1 (en) * | 2008-11-07 | 2010-05-14 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
JP5405592B2 (en) | 2008-12-23 | 2014-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | Dihydropyridone amide as a P2X7 modulator |
CA2747925A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone amides as p2x7 modulators |
EP2393781B1 (en) | 2008-12-23 | 2014-03-12 | F. Hoffmann-La Roche AG | Dihydropyridone ureas as p2x7 modulators |
SG172336A1 (en) | 2008-12-23 | 2011-07-28 | Hoffmann La Roche | Dihydropyridone amides as p2x7 modulators |
US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
EP2413958A4 (en) | 2009-03-31 | 2014-04-02 | Univ East Carolina | Cytokines and neuroantigens for treatment of immune disorders |
AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011011964A (en) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX2011012829A (en) * | 2009-06-02 | 2012-02-28 | Salix Pharmaceuticals Ltd | Methods of treating hepatic encephalopathy. |
WO2011039528A1 (en) | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
CN102241667B (en) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof |
PL2649069T3 (en) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
ES2536433T3 (en) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
ITMI20111952A1 (en) | 2011-10-27 | 2013-04-28 | Italiana Sint Spa | PROCEDURE FOR THE PREPATION OF 2-METHOXY-5- (PIRIDIN-2-IL) PYRIDINE, AN INTERMEDIATE OF THE PERAMPANEL |
EP2771031B1 (en) * | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
EP2800747A4 (en) | 2012-01-03 | 2015-12-09 | Mapi Pharma Ltd | Polymorphs of perampanel |
ITMI20121390A1 (en) | 2012-08-06 | 2014-02-07 | F I S Fabbrica Italiana Sint P A | PROCEDURE FOR THE PREPARATION OF 2-CYANOPHENYLBORONIC ACID AND ITS ESTERS, INTERMEDIATE OF THE PERAMPANEL OR E2040 |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
TW201441193A (en) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | Pyridone compound |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP3063139B1 (en) | 2013-10-29 | 2018-11-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN104725301A (en) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | Preparation method of 1,2-dihydropyridin-2-one derivative |
DK3096790T3 (en) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE |
UA127921C2 (en) | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US20160339040A1 (en) | 2014-01-29 | 2016-11-24 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
CN105085382B (en) * | 2014-05-14 | 2019-10-18 | 江苏豪森药业集团有限公司 | Pyrrole Lun Panai isomers crystal form and its preparation method and application |
MX2016016458A (en) * | 2014-06-30 | 2017-07-13 | Salix Pharmaceuticals Inc | Methods for retreating irritable bowel syndrome (ibs). |
UY36294A (en) | 2014-09-12 | 2016-04-29 | Novartis Ag | COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS |
CN104649963A (en) * | 2015-01-12 | 2015-05-27 | 苏州莱克施德药业有限公司 | Preparation technology of perampanel intermediate |
AR103384A1 (en) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA AS GABA MODULATOR |
BR112017016465B1 (en) * | 2015-02-04 | 2023-11-14 | Beyondbio Inc | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT |
EP3259262A4 (en) * | 2015-02-17 | 2018-08-01 | Mapi Pharma Limited | Process and intermediates for the preparation of perampanel |
WO2016147104A1 (en) * | 2015-03-14 | 2016-09-22 | Intas Pharmaceuticals Ltd. | Novel process for the preparation of perampanel and its intermediates thereof |
AR104259A1 (en) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | BROMODOMINUM INHIBITORS |
WO2017004811A1 (en) * | 2015-07-08 | 2017-01-12 | 中国食品发酵工业研究院 | Active peptide for inhibiting ampa receptor and preparation method and use thereof |
CN106892897A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of hydroxyl piperazine pyrrone free alkali novel crystal forms and preparation method thereof |
CN106928187A (en) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | A kind of hydrochloric acid hydroxyl piperazine pyrrone novel crystal forms and preparation method thereof |
WO2017127602A1 (en) * | 2016-01-22 | 2017-07-27 | Rush University Medical Center | Identification of novel small molecule beta2 integrin agonists |
EP3251662A1 (en) * | 2016-06-07 | 2017-12-06 | Tolerogenics S.à.r.l. | Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy |
CN116082225A (en) * | 2016-08-08 | 2023-05-09 | 北京康蒂尼药业股份有限公司 | Preparation method of hydroxynisone |
CN107698498A (en) * | 2016-08-08 | 2018-02-16 | 罗楹 | A kind of preparation method of oxycodone |
CN110028442B (en) * | 2018-01-11 | 2020-07-17 | 新发药业有限公司 | Simple preparation method of Perampanel |
CN108299428B (en) * | 2018-04-04 | 2019-09-27 | 山东大学 | 8- amido -7- methyl formate-pyrazine a pair of horses going side by side Pyridione derivatives and the preparation method and application thereof |
EP3560934A1 (en) | 2018-04-26 | 2019-10-30 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040 |
CN113633708B (en) * | 2021-09-27 | 2022-02-11 | 重庆希尔安药业有限公司 | Preparation method of stable bruise treating qili composition tablet |
WO2023192491A2 (en) * | 2022-03-30 | 2023-10-05 | Transposon Therapeutics, Inc. | Nucleoside line-1 inhibitors |
CN115403515B (en) * | 2022-04-25 | 2023-09-08 | 山东达因海洋生物制药股份有限公司 | Preparation method and application of pirenzenenaphthalene degradation impurity |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
CN115160217B (en) * | 2022-08-04 | 2023-09-22 | 山东达因海洋生物制药股份有限公司 | Preparation method of pirenzenenaphthalene, synthetic intermediate and preparation method of degradation impurity |
US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5283761A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Novel pyridone derivative |
JPS5531072A (en) | 1979-07-30 | 1980-03-05 | Rikagaku Kenkyusho | Preparation of 2-pyridone compound |
AU673660C (en) * | 1991-12-18 | 2002-07-25 | Astrazeneca Ab | New combination of formoterol and budesonide |
IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
HU219777B (en) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optical active 1-(4-nitrophenyl)-4-methyl-7,8-methylen dioxi-3,4-dihydro-5h-2,3-benzodiazepine and process for producing it |
ZA952797B (en) | 1994-04-12 | 1996-10-07 | Res Dev Foundation | Method of treating auto-immune diseases using type one interferons |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
WO1996010023A1 (en) | 1994-09-27 | 1996-04-04 | Yamanouchi Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxalindione derivative |
CN1188401C (en) | 1995-04-27 | 2005-02-09 | 三菱制药株式会社 | Heterocyclic amide compound and its pharmaceutical use |
US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
DE19604920A1 (en) | 1996-02-01 | 1997-08-07 | Schering Ag | New 2,3-benzodiazepine derivatives, their production and use as medicines |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
KR100375155B1 (en) | 1996-05-15 | 2003-08-19 | 화이자 인코포레이티드 | Novel 2,3-disubstituted-4(3h)-quinazolinones |
DE19643037A1 (en) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | New oxadiazoles, processes for their preparation and their use as medicines |
CN1248248A (en) | 1997-02-28 | 2000-03-22 | 辉瑞产品公司 | Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists |
GB9708945D0 (en) | 1997-05-01 | 1997-06-25 | Merck Sharp & Dohme | Therapeutic agents |
GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
JP4321737B2 (en) | 1997-12-17 | 2009-08-26 | 塩野義製薬株式会社 | New pyridine compounds |
WO2000001376A2 (en) * | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
DE19835918A1 (en) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | New anticonvulsant 4-amino-1-aryl-pyridin-2-ones and process for their preparation |
US6403596B1 (en) * | 1999-06-28 | 2002-06-11 | Merck & Co., Inc. | Substituted pyridones having cytokine inhibitory activity |
US6949571B2 (en) | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
CN1203055C (en) * | 2001-09-26 | 2005-05-25 | 朱德煦 | Method and composition for treating or preventing bacterial infection |
JP2004147535A (en) * | 2002-10-29 | 2004-05-27 | Japan Science & Technology Agency | Guillain-barre syndrome and / or fisher syndrome-developing model non-human animal |
-
2001
- 2001-12-06 GB GBGB0129260.6A patent/GB0129260D0/en not_active Ceased
-
2002
- 2002-12-06 WO PCT/GB2002/005542 patent/WO2003047577A2/en active IP Right Grant
- 2002-12-06 MX MXPA04005376A patent/MXPA04005376A/en active IP Right Grant
- 2002-12-06 AU AU2002347365A patent/AU2002347365B2/en not_active Ceased
- 2002-12-06 BR BR0214705-0A patent/BR0214705A/en not_active IP Right Cessation
- 2002-12-06 DE DE60228761T patent/DE60228761D1/en not_active Expired - Lifetime
- 2002-12-06 IL IL16221402A patent/IL162214A0/en unknown
- 2002-12-06 HU HU0402497A patent/HU228328B1/en not_active IP Right Cessation
- 2002-12-06 BR BRPI0214705-0A patent/BRPI0214705B1/en unknown
- 2002-12-06 EP EP02783299A patent/EP1465626B1/en not_active Expired - Lifetime
- 2002-12-06 US US10/497,518 patent/US7759367B2/en not_active Expired - Fee Related
- 2002-12-06 PT PT02783299T patent/PT1465626E/en unknown
- 2002-12-06 CA CA2469076A patent/CA2469076C/en not_active Expired - Fee Related
- 2002-12-06 JP JP2003548832A patent/JP4610898B2/en not_active Expired - Fee Related
- 2002-12-06 DK DK02783299T patent/DK1465626T3/en active
- 2002-12-06 AT AT02783299T patent/ATE406893T1/en active
- 2002-12-06 ES ES02783299T patent/ES2311635T3/en not_active Expired - Lifetime
- 2002-12-06 KR KR1020047008695A patent/KR100945822B1/en active IP Right Grant
- 2002-12-06 RU RU2004120538/15A patent/RU2358733C2/en not_active IP Right Cessation
- 2002-12-06 CN CN028279263A patent/CN1738618B/en not_active Expired - Fee Related
- 2002-12-06 NZ NZ533798A patent/NZ533798A/en not_active IP Right Cessation
- 2002-12-06 SI SI200230770T patent/SI1465626T1/en unknown
-
2004
- 2004-05-30 IL IL162214A patent/IL162214A/en not_active IP Right Cessation
- 2004-06-02 ZA ZA2004/04330A patent/ZA200404330B/en unknown
- 2004-06-03 NO NO20042298A patent/NO333627B1/en not_active IP Right Cessation
-
2008
- 2008-11-19 CY CY20081101334T patent/CY1108578T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20042298L (en) | Pharmaceutical preparations and their uses | |
WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
CA2449729A1 (en) | Prodrugs of gaba analogs, compositions and uses thereof | |
NO20053855D0 (en) | 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. | |
HUP0104718A2 (en) | Micronized eplerenone compositions and process for their preparation | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
DK1427708T3 (en) | Amino-phthalazinone derivatives such as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing the same | |
IL123002A0 (en) | 1-Phenyl-2- phenylacetoxy- ethanone derivatives | |
EP1562897A4 (en) | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease | |
ATE277929T1 (en) | IMMUNOSUPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | |
ATE245977T1 (en) | THERAPEUTIC SUBSTITUTED GUANIDINES | |
DE602004017871D1 (en) | PREPARATIONS FOR THE TREATMENT OF ARTHRITICAL APPEARANCE | |
DK1032556T3 (en) | Pharmaceutically active compounds and methods of use | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
NO20010940D0 (en) | TAN-1057 derivatives | |
AU4568400A (en) | Sphingomyelinase inhibitor | |
ATE315038T1 (en) | ANTIBACTERIAL AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |